Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Breast Cancer Female
Interventions: Observation of Exercise Program Adherence; Other
Lead sponsor: Colin Champ, MD; Other
Eligibility: 20 Years to 89 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mucopolysaccharidosis I
Interventions: No Intervention; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Cardiac Disease
Interventions: Edoxaban, Standard of Care (SOC); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Interventions: FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter; Device
Lead sponsor: Holly L Hedrick, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Keratosis, Actinic
Interventions: Tirbanibulin; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Infectious Diseases
Interventions: Observational procedures; Other
Lead sponsor: Hoskinson Health and Wellness Clinic; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gillette, Wyoming

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: ZB716, Palbociclib; Drug
Lead sponsor: EnhancedBio USA Inc.; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Agitation,Psychomotor
Interventions: Loxapine 10 MG; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions: CCH-aaes, Observation; Biological · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Glendale, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 33 more

Conditions: Prostate Cancer
Interventions: Relugolix, Leuprorelin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more

Conditions: Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome, Post-COVID-19 Condition, Postural Orthostatic Tachycardia Syndrome, Lyme Disease, Post-Treatment Lyme Disease Syndrome, Fibromyalgia, Cancer-Related Fatigue, Neuromuscular Diseases, Fatigue, POLG-Related Disorders
Interventions: Mito Map Energy Score and Home Functional Assessments; Other
Lead sponsor: AI Agent Vault, Inc. d/b/a Precision Mito; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: REGN2810, Platinum-doublet chemotherapy; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 49
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Daly City, California + 46 more

Conditions: Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions: Allogeneic natural killer (NK) cell; Genetic
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more

Conditions: Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Interventions: Rina-S, Bevacizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Miami, Florida • Sarasota, Florida • Towson, Maryland + 6 more

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Isotretinoin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more

Conditions: Vascular Anomalies, Vascular Anomaly, TIE2/PIK3CA Pathway Driven Vascular Anomalies
Interventions: alpelisib (BYL719); Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 30 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, long acting; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 4 more

Conditions: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions: Lumacaftor Plus Ivacaftor Combination, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 91
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more

Conditions: Metastatic Solid Neoplasm, Lymphoma
Interventions: SYNB1891, Atezolizumab; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Fever
Interventions: Intravenous acetaminophen plus oral placebo, Oral acetaminophen plus IV placebo, Reference standard endotoxin (RSE); Drug · Biological
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA

Long Term Follow-Up for RGX-111

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Safety and Efficacy of FETO in CDH: A Phase III Trial

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

Rapamycin and Infection-related Illness

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

The Precision Mito- Mito Map COMPASS Study

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males